Abstract: An antenna and a fabrication method of the antenna are provided. The antenna includes a plurality of sub-antennas arranged in an array. A sub-antenna of the plurality of sub-antennas includes a first substrate and a second substrate that are disposed opposite to each other, a dielectric function layer disposed between the first substrate and the second substrate, a ground metal layer disposed on a side of the first substrate facing towards the dielectric function layer, and a metal connector. The first substrate of each sub-antenna is coplanar with each other, and the second substrate of each sub-antenna is coplanar with each other. A spliced region is formed between adjacent two sub-antennas of the plurality of sub-antennas, and in the spliced region, two first substrates of the adjacent two sub-antennas are connected by the metal connector.

Abstract: An antenna and a fabrication method of the antenna are provided. The antenna includes a plurality of sub-antennas arranged in an array. A sub-antenna of the plurality of sub-antennas includes a first substrate and a second substrate that are disposed opposite to each other, a dielectric function layer disposed between the first substrate and the second substrate, a ground metal layer disposed on a side of the first substrate facing towards the dielectric function layer, and a metal connector. The first substrate of each sub-antenna is coplanar with each other, and the second substrate of each sub-antenna is coplanar with each other. A spliced region is formed between adjacent two sub-antennas of the plurality of sub-antennas, and in the spliced region, two first substrates of the adjacent two sub-antennas are connected by the metal connector.

Abstract: Provided are a liquid crystal antenna and a preparation method of the liquid crystal antenna. The liquid crystal antenna includes a liquid crystal cell and the liquid crystal cell includes a first substrate, a second substrate, a microstrip line, a ground metal layer, a liquid crystal layer, and frame glue. The liquid crystal antenna further includes a third substrate, a fourth substrate, and a radiation electrode. The third substrate extends beyond an edge of the first substrate. The fourth substrate extends beyond edges of the second substrate on at least two sides. A connection structure is disposed between the third substrate and the fourth substrate, and the connection structure is disposed on an outer side of the frame glue. The liquid crystal antenna and the preparation method of the liquid crystal antenna are provided to reduce preparation difficulty and improve reliability.

Abstract: Provided herein are methods of treating a patient having a cancer that exhibits (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) expression level. The methods comprise administering a therapeutically effective amount of a POLR2A inhibitor (e.g., a nucleic acid that inhibits the expression of a POLR2A protein, an amatoxin, alpha-amanitin, or alpha-amanitin conjugated to a cell targeting moiety, such as an EpCAM antibody) to a patient having or determined to have (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) level.

Abstract: Provided are a liquid crystal antenna and a preparation method of the liquid crystal antenna. The liquid crystal antenna includes a liquid crystal cell and the liquid crystal cell includes a first substrate, a second substrate, a microstrip line, a ground metal layer, a liquid crystal layer, and frame glue. The liquid crystal antenna further includes a third substrate, a fourth substrate, and a radiation electrode. The third substrate extends beyond an edge of the first substrate. The fourth substrate extends beyond edges of the second substrate on at least two sides. A connection structure is disposed between the third substrate and the fourth substrate, and the connection structure is disposed on an outer side of the frame glue. The liquid crystal antenna and the preparation method of the liquid crystal antenna are provided to reduce preparation difficulty and improve reliability.

Abstract: A steel for high-strength aluminum clad substrate, comprising the following chemical elements by mass percent: C: 0.008-0.02%, 0<Si?0.005%, Mn: 0.25-0.5%, P: 0.018-0.03%, Al?0.005%, N: 0.0040-0.010%, Ti: 0.02-0.04%, O: 0.02-0.050%, and the balance being Fe and other inevitable impurities. The manufacturing method therefor comprises the steps of: (1) smelting and casting; (2) reheating: reheating a casting blank to 1180° C.-1250° C.; (3) rough rolling; (4) finish rolling; (5) coiling; and (6) cooling to room temperature. The steel for high-strength aluminum clad substrate has good strength and good plasticity.

Abstract: The present invention provides a flavor extract of low-temperature-pressed peanut cake which is extracted from low-temperature-pressed peanut cake. In the flavor extract, the content of pyrazines flavor substances is not less than 55%, and the content of the aldehydes substances is not more than 15%. The present invention also provides a method for improving the flavor of peanut oil by using the flavor extract of the low-temperature-pressed peanut cake. The flavor extract extracted from peanut cake according to the present invention, which contains 55% or more pyrazines flavor substances, can not only improve the flavor of low-temperature-pressed peanut oil significantly, but also retain the original quality and color of the low-temperature-pressed peanut oil when it is added to low-temperature-pressed peanut oil.

Abstract: Provided herein are methods of treating a patient having a cancer that exhibits (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) expression level. The methods comprise administering a therapeutically effective amount of a POLR2A inhibitor (e.g., a nucleic acid that inhibits the expression of a POLR2A protein, an amatoxin, alpha-amanitin, or alpha-amanitin conjugated to a cell targeting moiety, such as an EpCAM antibody) to a patient having or determined to have (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) level.

Abstract: Provided herein are methods of treating a patient having a cancer that exhibits (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) expression level. The methods comprise administering a therapeutically effective amount of a POLR2A inhibitor (e.g., a nucleic acid that inhibits the expression of a POLR2A protein, an amatoxin, alpha-amanitin, or alpha-amanitin conjugated to a cell targeting moiety, such as an EpCAM antibody) to a patient having or determined to have (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) level.

Abstract: The present invention provides a flavor extract of low-temperature-pressed peanut cake which is extracted from low-temperature-pressed peanut cake. In the flavor extract, the content of pyrazines flavor substances is not less than 55%, and the content of the aldehydes substances is not more than 15%. The present invention also provides a method for improving the flavor of peanut oil by using the flavor extract of the low-temperature-pressed peanut cake. The flavor extract extracted from peanut cake according to the present invention, which contains 55% or more pyrazines flavor substances, can not only improve the flavor of low-temperature-pressed peanut oil significantly, but also retain the original quality and color of the low-temperature-pressed peanut oil when it is added to low-temperature-pressed peanut oil.

Abstract: Provided herein are methods of treating a patient having a cancer that exhibits (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) expression level. The methods comprise administering a therapeutically effective amount of a POLR2A inhibitor (e.g., a nucleic acid that inhibits the expression of a POLR2A protein, an amatoxin, alpha-amanitin, or alpha-amanitin conjugated to a cell targeting moiety, such as an EpCAM antibody) to a patient having or determined to have (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) level.

Abstract: Tea polyphenols are used to prevent or treat tumors such as leukemia and myeloma, malignant tumors in a hematopoietic system. The tea polyphenols are tea extracts comprising EGCG, EGC, and ECG, or Tegreen97®, a green tea capsule of PHARMANEX, INC.

Abstract: Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors is provided. The tea polyphenols are tea extracts comprising EGCG, EGC, and ECG, or Tegreen 97®, a green tea capsule of PHARMANEX, INC.